EDT Stock Overview
Focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Spectral Medical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.57 |
| 52 Week High | CA$0.75 |
| 52 Week Low | CA$0.33 |
| Beta | 1 |
| 11 Month Change | 1.79% |
| 3 Month Change | -17.39% |
| 1 Year Change | 67.65% |
| 33 Year Change | 128.00% |
| 5 Year Change | 1.79% |
| Change since IPO | -98.43% |
Recent News & Updates
Shareholder Returns
| EDT | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | -11.9% | 0.6% |
| 1Y | 67.6% | -2.0% | 21.5% |
Return vs Industry: EDT exceeded the Canadian Biotechs industry which returned 6.3% over the past year.
Return vs Market: EDT exceeded the Canadian Market which returned 23.7% over the past year.
Price Volatility
| EDT volatility | |
|---|---|
| EDT Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: EDT has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: EDT's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 29 | Chris Seto | spectraldx.com |
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.
Spectral Medical Inc. Fundamentals Summary
| EDT fundamental statistics | |
|---|---|
| Market cap | CA$147.06m |
| Earnings (TTM) | -CA$25.00m |
| Revenue (TTM) | CA$2.01m |
80.4x
P/S Ratio-6.4x
P/E RatioIs EDT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EDT income statement (TTM) | |
|---|---|
| Revenue | CA$2.01m |
| Cost of Revenue | CA$1.21m |
| Gross Profit | CA$798.00k |
| Other Expenses | CA$25.80m |
| Earnings | -CA$25.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.088 |
| Gross Margin | 39.78% |
| Net Profit Margin | -1,246.31% |
| Debt/Equity Ratio | -41.2% |
How did EDT perform over the long term?
See historical performance and comparison